_manduul-and-delgerel-hashimoto39s-disease-preview-1.jpg "MANDUUL and DELGERELХашимотогийнэмгэг Hashimoto's Diseaseтухай ярилцав. from umrd Video Screenshot Preview 1")
Gallery_manduul-and-delgerel-hashimoto39s-disease-preview-3.jpg "MANDUUL and DELGERELХашимотогийнэмгэг Hashimoto's Diseaseтухай ярилцав. from umrd Video Screenshot Preview 3")
Gallery_manduul-and-delgerel-hashimoto39s-disease-preview-hqdefault.jpg "MANDUUL and DELGERELХашимотогийнэмгэг Hashimoto's Diseaseтухай ярилцав. from umrd Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 1 hour 1 minute 19 seconds
👁 View: 39.9K times
Play Audio:👁 View: 39.9K times
Description:
MANDUULERO
MANDUULERO
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_glow-study-mrd-outcomes-after-fixed-duration-ibrven-versus-clbo-for-first-line-treatment-of-cll-in-elderly-or-unfit-pati.webp "Dr Arnon Kater speaks to ecancer about the Glow study. nnThis is the first prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients. nnInitially, he explains the background of the Glow study. nnDr Kater then discusses the methods and key results. All-oral, once-daily, fixed-duration Ibr+Ven demonstrated superior uMRD responses that")
⏲ 3 min 48 sec ✓ 14-Dec-2021
_mrd-guided-acalabrutinib-venetoclax-and-obinutuzumab-therapy-for-cll-ash-2023.webp "CLL Society")
⏲ 10 minutes 21 seconds 👁 125
_ibrutinib-venetoclax-for-chronic-lymphocytic-leukemia-cll-treatment-dr-bill-wierda-ash-2022.webp "CLL Society")
⏲ 6 minutes 39 seconds 👁 117
_captivate-fixed-duration-first-line-treatment-with-ibrutinib-plus-venetoclax-for-cll-sll.webp "Dr Rajat Bannerji speaks to ecancer about the CAPTIVATE study. nnIt is a trial investigating a fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL. nnInitially, he explains the background of the study. Dr Bannerji then discusses the methodology and results of the study. nnHe mentions that first-line I+V is an all-oral, once-daily, chemotherapy-free, fixed-duration regimen that provides deep, durable responses in patients with CLL/SLL, including those with genomic high-")
⏲ 6 min 82 sec ✓ 10-Jun-2021
_124-124-ethiopia-orthodox-eotc.webp "Maldo Media ( ማልዶ ሚዲያ )")
⏲ 10 minutes 20 seconds 👁 741
_124-124ethiopia-orthodox-eotc.webp "Maldo Media ( ማልዶ ሚዲያ )")
⏲ 19 minutes 17 seconds 👁 540
_sedet.webp "Hamelmal Abate")
_atham-addus-feat-ali-birra-makhtut-hirat.webp "Atham Addus")
_glow-study-mrd-outcomes-after-fixed-duration-ibrven-versus-clbo-for-first-line-treatment-of-cll-in-elderly-or-unfit-pati.jpg)
_mrd-guided-acalabrutinib-venetoclax-and-obinutuzumab-therapy-for-cll-ash-2023.jpg)
_ibrutinib-venetoclax-for-chronic-lymphocytic-leukemia-cll-treatment-dr-bill-wierda-ash-2022.jpg)
_captivate-fixed-duration-first-line-treatment-with-ibrutinib-plus-venetoclax-for-cll-sll.jpg)
_124-124-ethiopia-orthodox-eotc.jpg)
_124-124ethiopia-orthodox-eotc.jpg)
_sedet.jpg)
_atham-addus-feat-ali-birra-makhtut-hirat.jpg)
![[+]](/images/menu.gif){kind=small}